Eliminate Malaria

We are committed to making a major contribution in efforts to eliminate malaria as a public health threat, particularly in our region.

One of the leading causes of mortality and morbidity globally, malaria was responsible for more than 627,000 deaths, and 241 million clinical cases in 2020 – an increase of 12% compared to the previous year, according the WHO’s latest World Malaria Report. An estimated 2.5 billion people are at risk of the disease, with young children and pregnant women most affected.

A two-way pipeline will be created where our research discoveries can be tested in the field, and field programs inform discovery research through our long-standing connections with vulnerable target populations, especially in Papua New Guinea and Myanmar.

Through this program, Burnet will contribute to:

  • reaching the WHO elimination targets of a 90 percent reduction in malaria incidence and mortality through an active program of basic, discovery and translational research and in-field education, prevention and treatment programs.

  • supporting country programs in our region that assist WHO in reaching targets of elimination in at least 35 countries by 2030.

Discover more about Burnet’s malaria work in Episode 8 of our How Science Matters podcast.

Contact Details

Professor James Beeson

MBBS, BMedSc, PhD, FAFPHM, FAAHMS | Deputy Director (People); Head of Malaria Immunity and Vaccines Laboratory; Adjunct Professor Monash University






  • Antibody engineering to study responses mediating protective immunity

  • Clinical studies on malaria

  • Decision science using Optima

  • Developing new antimalarial drugs that block protein trafficking

  • Developing vaccines against malaria

  • Discovering the mechanisms and targets of immunity against malaria

  • Evaluating a highly sensitive rapid malaria diagnostic in PNG

  • Evaluation of Malaria Case-Based Reporting using a mobile phone application in Myanmar

  • Host and parasite factors that predict Artemisinin Resistance reservoirs

  • Host red blood cell modification sustains the virulence of malaria parasites

  • Immunity to malaria and infectious diseases during pregnancy

  • Immunity, drug efficacy and spread of antimalarial drug resistance

  • Impact of declining transmission on immunity and risk of malaria rebound

  • Major advances in understanding malaria immunity and biology

  • Mechanism of antimalarial drug action

  • NATNAT: Newly Adapted Tools and Network Against Mosquito Borne Disease Transmission

  • Optima Malaria Modelling

  • Optimal community-delivered malaria elimination models for the Greater Mekong Sub-region

  • Predicting quality and potency of monoclonal and natural antibodies

  • Serological surveillance to identify mosquito exposure and malaria transmission

  • Stellabody® Technology in Infectious Disease – COVID-19 and beyond

  • STRIVE PNG: Stronger Surveillance and Systems Support for Rapid Identification and Containment of Resurgent or Resistant Vector-Borne Pathogens in Papua New Guinea

  • Vaccines against Plasmodium vivax and P. falciparum malaria

Latest News

    20 December, 2022

    2022 in Review: July to December

    The second half of 2022 saw Burnet launch its 2030 strategy, and continue important work in life sciences, public health and international development.

    20 December, 2022

    2022 in Review: January to June

    As the third year of the pandemic got underway, Burnet continued its COVID-19 advocacy around a vaccines plus approach and advanced important work in malaria, tuberculosis and hepatitis C.